Reimagining Cancer Care: Why We Can Not Accept the Status Quo
Working at Daiichi Sankyo, cancer was part of my everyday life. But this was different. This was my dad, and it was a diagnosis I knew would not end with the ringing of a bell…
Content with Our Story .
HER2 in Gynecologic Cancers—Why It Matters
In certain cancers, HER2 becomes overexpressed or uncontrolled, driving tumors to develop quickly. As our understanding of HER2 and its role deepens, its relevance across endometrial, ovarian and other gynecologic tumors has become…
Turning Complexity into Hope in Honor of My Father
My decision to devote my career to oncology is deeply personal. During my senior year in college, my father was diagnosed with cholangiocarcinoma, or bile duct cancer. As one of his caregivers…
Understanding Metastatic Breast Cancer: Exploring the Science
Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.
Crafting Meaningful Connections to Benefit Patients
Business development is the craft of making connections. Whether with other companies or within our organization, we need to build those bonds that allow us to be successful.
Beyond Positive & Negative: The Spectrum of HER2 Expression in Cancer
Cancer research and development is a dynamic and ever-evolving field. One significant area of focus is the role of HER2.
Daiichi Sankyo’s HER2 Directed ADC Receives Industry’s Top Award
The Galien Foundation has recognized Daiichi Sankyo’s HER2 directed antibody drug conjugate (ADC) with the prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.